0000899243-21-018121.txt : 20210504
0000899243-21-018121.hdr.sgml : 20210504
20210504163102
ACCESSION NUMBER: 0000899243-21-018121
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210504
FILED AS OF DATE: 20210504
DATE AS OF CHANGE: 20210504
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arkin Moshe
CENTRAL INDEX KEY: 0001321178
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40366
FILM NUMBER: 21889005
MAIL ADDRESS:
STREET 1: 6 HACHOSHLIM ST.
CITY: HERZELIA
STATE: L3
ZIP: 4672406
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arkin Bio Ventures GPGP Ltd.
CENTRAL INDEX KEY: 0001858707
STATE OF INCORPORATION: L3
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40366
FILM NUMBER: 21889006
BUSINESS ADDRESS:
STREET 1: 6 HA CHOSHLIM ST.
STREET 2: BUILDING C, 6TH FLOOR
CITY: HERZLIYA
STATE: L3
ZIP: 4672406
BUSINESS PHONE: 972-97883330
MAIL ADDRESS:
STREET 1: 6 HA CHOSHLIM ST.
STREET 2: BUILDING C, 6TH FLOOR
CITY: HERZLIYA
STATE: L3
ZIP: 4672406
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arkin Bio Ventures 2 L.P.
CENTRAL INDEX KEY: 0001858705
STATE OF INCORPORATION: L3
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40366
FILM NUMBER: 21889007
BUSINESS ADDRESS:
STREET 1: 6 HA CHOSHLIM ST.
STREET 2: BUILDING C, 6TH FLOOR
CITY: HERZLIYA
STATE: L3
ZIP: 4672406
BUSINESS PHONE: 972-97883330
MAIL ADDRESS:
STREET 1: 6 HA CHOSHLIM ST.
STREET 2: BUILDING C, 6TH FLOOR
CITY: HERZLIYA
STATE: L3
ZIP: 4672406
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Werewolf Therapeutics, Inc.
CENTRAL INDEX KEY: 0001785530
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 823523180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1030 MASSACHUSETTS AVENUE
STREET 2: SUITE 210
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
BUSINESS PHONE: 617-952-0555
MAIL ADDRESS:
STREET 1: 1030 MASSACHUSETTS AVENUE
STREET 2: SUITE 210
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-05-04
1
0001785530
Werewolf Therapeutics, Inc.
HOWL
0001858705
Arkin Bio Ventures 2 L.P.
6 HACHOSHLIM STREET
HERZLIYA PITUACH
L3
4672406
ISRAEL
0
0
1
0
0001858707
Arkin Bio Ventures GPGP Ltd.
6 HACHOSHLIM STREET
BUILDING C
HERZLIYA PITUACH
L3
4672406
ISRAEL
0
0
1
0
0001321178
Arkin Moshe
6 HACHOSHLIM ST.
HERZELIA
L3
4672406
ISRAEL
0
0
1
0
Common Stock
2021-05-04
4
C
0
1235917
A
1235917
I
See footnote
Common Stock
2021-05-04
4
C
0
410717
A
1646634
I
See footnote
Common Stock
2021-05-04
4
P
0
400000
16.00
A
2046634
I
See footnote
Series A Preferred Stock
2021-05-04
4
C
0
10714284
0.00
D
Common Stock
1235917
0
I
See footnote
Series B Preferred Stock
2021-05-04
4
C
0
3560551
0.00
D
Common Stock
410717
0
I
See footnote
On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund.
On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
This Form 4 shall not be construed as an admission by any of the Reporting Persons or any other entity named in this Form 4 that it is the beneficial owner of any of the securities covered by this Form 4, and each such Reporting Person or entity disclaims beneficial ownership of any such securities, except to the extent of its pecuniary interest therein.
Arkin Bio Ventures 2 L.P., By: Its ultimate General Partner, Arkin Bio Ventures GPGP Ltd., By: Its sole shareholder and Chairman of the Board, Moshe Arkin, By: /s/ Yair Ben Yosef, attorney-in-fact
2021-05-04
Arkin Bio Ventures GPGP Ltd., By: Its sole shareholder and Chairman of the Board, Moshe Arkin, By: /s/ Yair Ben Yosef, attorney-in-fact
2021-05-04
Moshe Arkin, By: /s/ Yair Ben Yosef, attorney-in-fact
2021-05-04